#516 on the rich list of 14,452 insiders
Pablo G. Legorreta
CEO, Chairman of the Board at Royalty Pharma; Director at ProKidney. Based in New York, New York.
$448M
in disclosed stock, −$2.6M (−0.57%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
- Rank
- 516th of 14,452
- Companies held
- 2
- Largest holding
- RPRX, 74.7% of total
- Latest SEC filing
- Nov 4, 2026
What the $448M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Royalty Pharma RPRX Class A Ordinary Shares | Directly | 1,350,029 | $67.72 | $91.4M | 20.4% | Form 4, Nov 4, 2026 |
| ProKidney PROK Class B Ordinary Shares | Indirectly (see filing footnote) | 84,283,430 | $1.06 | $89.3M | 19.9% | Form 4, Jun 3, 2025 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Legorreta Children 2002 Trust | 1,040,410 | $67.72 | $70.5M | 15.7% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through GST-Exempt Legorreta 2012 Family Trust | 901,590 | $67.72 | $61.1M | 13.6% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Legorreta 2023 SR Trust | 600,000 | $67.72 | $40.6M | 9.1% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Legorreta Investments LLC | 460,139 | $67.72 | $31.2M | 7.0% | Form 4, Nov 4, 2026 |
| ProKidney PROK Class A Ordinary Shares | Indirectly (see filing footnote) | 22,617,909 | $1.06 | $24.0M | 5.3% | Form 4, Jun 3, 2025 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Tata MC 35 Ltd. | 292,190 | $67.72 | $19.8M | 4.4% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through IRRA | 123,310 | $67.72 | $8.4M | 1.9% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through SEP/IRA | 118,500 | $67.72 | $8.0M | 1.8% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through GST-Exempt Legorreta 2020 Family Trust | 41,306 | $67.72 | $2.8M | 0.6% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Son | 10,000 | $67.72 | $677K | 0.2% | Form 4, Nov 4, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through Spouse | 6,930 | $67.72 | $469K | 0.1% | Form 4, Nov 4, 2026 |
Share counts are the amounts Pablo G. Legorreta reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 513 | Severin Hacker Chief Tech Officer, Co-Founder, Duolingo. Pittsburgh, PA | $454M |
| 514 | Richard T. Burke Director, UnitedHealth Group. Minnetonka, MN | $454M |
| 515 | William H. Milmoe Insider, Celsius Holdings. Delray Beach, FL | $453M |
| 516 | Pablo G. Legorreta CEO, Chairman of the Board, Royalty Pharma. New York, NY | $448M |
| 517 | Yoshiyuki Aikawa Chairman and CEO, SBC Medical Group Holdings. Irvine, CA | $446M |
| 518 | Raul Marcelo Claure Director, T-Mobile US. Bellevue, WA | $445M |
| 519 | Keith Manchester Director, Roivant Sciences | $445M |
Other Royalty Pharma insiders
All RPRX insiders- George W. Lloyd$184MEVP, Investments & CLO. #939 overall
- Terrance P. Coyne$132MEVP & CFO. #1225 overall
- James F. Reddoch$57.3MEVP & Chief Scientific Officer. #2308 overall
- Rory B. Riggs$28.5MDirector. #2664 overall
- Christopher Hite$13.6MEVP & Chairman, Partnering. #6962 overall
- Gregory Norden$13.3MDirector. #6522 overall
Questions
How much stock does Pablo G. Legorreta own?
Pablo G. Legorreta holds $448,150,458 in listed stock based on SEC filings and current prices, mostly Royalty Pharma (RPRX). That ranks 516th on the Stock Rich List.
Is this Pablo G. Legorreta's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.